Conv. Plasma
Nigella Sativa

All aspirin studies
Meta analysis
study COVID-19 treatment researchAspirinAspirin (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Mortality -49% Improvement Relative Risk Aspirin for COVID-19  Pérez-Segura et al.  Prophylaxis Is prophylaxis with aspirin beneficial for COVID-19? Retrospective 763 patients in multiple countries Higher mortality with aspirin (p=0.00012) Pérez-Segura et al., Medicina Clínica, Oct 2021 Favors aspirin Favors control

Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data

Pérez-Segura et al., Medicina Clínica, doi:10.1016/j.medcle.2021.02.010
Oct 2021  
  Source   PDF   All   Meta
Aspirin for COVID-19
19th treatment shown to reduce risk in March 2021
*, now known with p = 0.00014 from 72 studies, recognized in 2 countries.
Lower risk for mortality and progression.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
4,000+ studies for 60+ treatments.
Retrospective 770 COVID-19 patients with cancer, showing increased mortality with aspirin use in unadjusted results.
risk of death, 49.1% higher, RR 1.49, p < 0.001, treatment 66 of 155 (42.6%), control 183 of 608 (30.1%), odds ratio converted to relative risk.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Pérez-Segura et al., 4 Oct 2021, retrospective, multiple countries, peer-reviewed, 23 authors.
This PaperAspirinAll
Prognostic factors at admission on patients with cancer and COVID-19: Analysis of HOPE registry data
Pedro Pérez-Segura, M Paz-Cabezas, I J Núñez-Gil, R Arroyo-Espliguero, C Maroun Eid, R Romero, I Fernández Rozas, A Uribarri, V M Becerra-Muñoz, M García Aguado, J Huang, E Rondano, E Cerrato, E Alfonso Rodríguez, M E Ortega-Armas, S Raposeiras Roubin, M Pepe, G Feltes, A Gonzalez, B Cortese, L Buzón, I El-Battrawy, V Estrada
Medicina Clínica, doi:10.1016/j.medcli.2021.02.021
Background: Previous works seem to agree in the higher mortality of cancer patients with COVID-19. Identifying potential prognostic factors upon admission could help identify patients with a poor prognosis. Methods: We aimed to explore the characteristics and evolution of COVID-19 cancer patients admitted to hospital in a multicenter international registry (HOPE COVID-19). Our primary objective is to define those characteristics that allow us to identify cancer patients with a worse prognosis (mortality within 30 days after the diagnosis of COVID-19). Results: 5838 patients have been collected in this registry, of whom 770 had cancer among their antecedents. In hospital mortality reached 258 patients (33.51%). The median was 75 years (65-82). Regarding the distribution by sex, 34.55% of the patients (266/770) were women. The distribution by type of cancer: genitourinary 238/745 (31.95%), digestive 124/745 (16.54%), hematologic 95/745 (12.75%). In multivariate regression analysis, factors that are independently associated with mortality at admis-
identification of factors predicting a worse prognosis, such as those presented here, can help us to better manage this process and try to reduce mortality from COVID-19 in the cancer patient. Conflict of interests The authors declare that they have no conflict of interest.
Alqahtani, Oyelade, Aldhahir, Alghamdi, Almehmadi et al., Prevalence, severity and mortality associated with COPD and smoking in patients with COVID-19: a rapid systematic review and meta-analysis, PLOS ONE, doi:10.1371/journal.pone.0233147
Blimark, Holmberg, Mellqvist, Landgren, Björkholm et al., Multiple mieloma and infections: a population-based study on 9253 multiple mieloma patients, Haematologica
Cdc, COVID-19 Response Team. Severe outcomes among patients with coronavirus disease 2019 (COVID-19) -United States, MMWR Morb Mortal Wkly Rep
Dai, Liu, Liu, Zhou, Li et al., Patients with cancer appear more vulnerable to SARS-Co-2: a multicenter study during the COVID-19 outbreak, Cancer Discov, doi:10.1158/2159-8290.CD-20-0422
Guan, Ni, Hu, Liang, Ou et al., Clinical characteristics of coronavirus disease 2019 in China, N Engl J Med
Kuderer, Choueiri, Shah, Shyr, Rubinstein et al., Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study, Lancet, doi:10.1016/S0140-6736(20)31187-9
Liang, Guan, Chen, Li, Xu, Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China, Lancet Oncol
Mehta, Goel, Kabarriti, Cole, Goldfinger et al., Case fatality rate of cancer patients with Covid-19 in a New York hospital system, Cancer Disc, doi:10.1158/2159-8290.CD-20-0516
Miyashita, Mikami, Chopra, Yamada, Chernyavsky et al., Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City, Ann Oncol, doi:10.1016/j.annonc.2020.04.006
Who, WHO Director-General's opening remarks at the media briefing con COVID-19
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop